Nabil El Halawany
Psychiatry · Raymore, MONPI 1790761260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $577 and has fallen 53.9% since, to $267 in 2025.
Across 93 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$334
- AbbVie$241
- Sunovion Pharmaceuticals Inc.$219
- Teva Pharmaceuticals USA, Inc.$210
- Takeda Pharmaceuticals U.S.A., Inc.$130
- Lundbeck LLC$107
- plus $668 from 17 others
What the payments were for
- Food & beverage$1,79794%
- Education$1116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 19 | $334 |
| AbbVie(2 entities) | 13 | $241 |
| Sunovion Pharmaceuticals Inc. | 8 | $219 |
| Teva Pharmaceuticals USA, Inc. | 6 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $130 |
| Lundbeck LLC | 5 | $107 |
| Otsuka America Pharmaceutical, Inc. | 6 | $104 |
| Boston Scientific | 1 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $44 |
| Alkermes, Inc. | 2 | $34 |
| Bausch Health US, LLC | 2 | $27 |
| Merck | 2 | $26 |
| Shire North American Group Inc | 2 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $13 |
| Neuronetics, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$112
How this compares
$1,909 in reported general payments places this provider in the 75th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 29 | $3,126 |
| Alprazolam | 42 | $363 |
| Gabapentin | 11 | $322 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $247 |
| Duloxetine Hcl | 11 | $88 |
| Escitalopram Oxalate | 19 | $72 |
| Clonazepam | 18 | $70 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Raymore
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.